Skip to main content

Advertisement

SpringerLink
Log in

Novel approaches on prodrug based drug design

  • Search for New Drugs
  • Published:
Pharmaceutical Chemistry Journal Aims and scope

An Erratum to this article was published on 01 February 2009

Prodrug design is really not different from the general drug discovery process, in which a unique substance is observed to have desirable pharmacological effects, and studies of its properties lead to the design of better drugs. It is a very fruitful way of research, and its introduction in human therapy has given successful results in improving the clinical and therapeutic effectiveness of drugs suffering from some undesirable properties that otherwise hinder their clinical usefulness. The present article reviews various prodrugs and their applications and presents the developments in this field during the last few decades. This review also highlights developing strategies in targeted prodrug design, including antibody-directed enzyme prodrug therapy, gene-directed enzyme prodrug therapy and peptide transporter-associated prodrug therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. S. L. Timofeevski, E. F. Pnarin, O. L. Vinogradov, et al., Pharm. Res., 13(3), 476–480 (1996).

    Article  PubMed  CAS  Google Scholar 

  2. A. Albert, Nature, No. 182, 421–423 (1958).

  3. N. Bodor and P. Buchwald, Med. Res. Rev., 20(1), 58–101 (2000).

    Article  PubMed  CAS  Google Scholar 

  4. A. Eltahir, S. D. Heys, A. W. Hutcheon, et al., Am. J. Surg., No. 175, 127–132 (1998).

  5. G. N. Hortobagyi, Drugs, No. 54, 1–7 (1997).

  6. F. L. Moolten, Cancer Res., No. 46, 5276–5281 (1986).

  7. A. A. Elshami, A. Saavedra, H. Zhang, et al., Gene Ther., No. 3, 85–92 (1996).

  8. S. M. Stribbling, F. Friedlos, J. Martin, et al., Human Gene Ther., No. 11, 258–292 (2000).

  9. S. M. Freeman, R. Ramesh, and A. J. Marrogi, Lancet, No. 349, 2–3 (1997).

  10. E. C. Mar, J. F. Chiou, Y. C. Cheng, et al., J. Virol., No. 56, 846–851 (1995).

  11. T. Tanaka, F. Kanai, S. Okabe, et al., Cancer Res., No. 56, 1341–1345 (1996).

  12. M Caruso, Y. Panis, S. Gagandeep, et al., Proc. Natl. Acad. Sci. USA, No. 90, 7024–7028 (1993)

  13. C. J. Springer and I. Niculescu-Duvaz, Adv. Drug Deliv. Rev., No. 22, 351–364 (1996).

  14. R. Sherwood, R. Melton, S. Alwan, et al., Eur. J. Biochem., No. 148, 447–453 (1985).

  15. K. D. Bagshawe, C. J. Springer, F. Searle, et al., Br. J. Cancer, No. 58, 700–703 (1988).

  16. R. G. Melton, F. Searle, R. F. Sherwood, et al., Br. J. Cancer, No. 61, 420–424 (1990).

  17. D. C. Blakey, B. E. Valcaccia, S. East, et al., Cell. Biophys., No. 22, 1–8 (1993)

  18. G. T. Rogers, P. J. Burke, S. K. Shama, et al., Br. J. Cancer, No. 72, 1357–1363 (1995).

  19. S. K. Shama, J. A. Boden, C. J. Springer, et al., Cell. Biophys., No. 24, 219–228 (1994).

  20. P. F. Torrence, J. Kinjo, S. Khamnei, et al., J. Med. Chem., No. 36, 529–537 (1993).

  21. C. K. Chu, V. S. Bhadti, K. J. Doshi, et al., J. Med. Chem., No. 33, 2188–2192 (1990).

  22. R. J. Whitley and J. W. Gnann, Engl. J. Med., No. 327, 782–788 (1992).

  23. L. D. Lewis, A. S. E. Fowle, and S. B. Bittiner, Br. J. Clin. Pharmacol., No. 21, 459–462 (1986).

  24. P. De Miranda and M. R. Blum, J. Antimicrob. Chemother., No. 12 (Suppl. B) 29–37 (1983).

  25. M. R. Boyd, T. H. Bacon, and D. Sutton, Antimicrob. Agents Chemother., No. 37, 642–645 (1993).

  26. R. A. Vere Hodge, D. Sutton, M. R. Boyd, et al., Antimicrob. Agents Chemother., No. 33, 1765–1773 (1989).

  27. F. Peuch, G. Gosselin, I. Lefebvre, et al., Antiviral Res., No. 22, 155–174 (1993).

  28. P. Rolan, Clin. Pharmacokinet., No. 29, 333–340 (1995).

  29. C. W. Filer, G. D. Allen, and T. A. Brown, Xenobiotica, No. 24, 357–368 (1994).

  30. E. B. Roche, Design of Biopharmaceutical Properties through Prodrugs and Analogs. Academy of Pharmaceutical Sciences Symposium, Washington DC (1977).

  31. J. K. Sastry, P. N. Nehete, S. Khan, et al., Mol. Pharmacol., No. 41, 441–445 (1992).

  32. A. Pompon, I. Lefebvre, J. Imbach, et al., Antiviral Chem. Chemother., No. 5, 91–98 (1994).

  33. D. Farquhar, S. Khan, D. N. Srivastva, et al., J. Med. Chem., No. 37, 3902–3909 (1994).

  34. R. J. Jones, M. N. Arimilli, M. S. Louie, et al., Abstract Op11; XII International Roundtable Nucleosides, Nucleotides and Their Biological Application, September 15–19, La Jolla, USA (1996).

  35. J. Balzarini, S. Aquaro, C. F. Perno, et al., Biochem. Biophys. Res. Commun., No. 219, 337–341 (1996).

  36. C. C. Tsai, K. E. Follis, A. Sabo, et al., Science, No. 270, 1197–1199 (1995).

  37. K. K. A. Van Rompay J. M. Cherrington, M. L. Marthas, et al., Antimicrob. Agents Chemother., No. 40, 2586–2591 (1996).

  38. J. L. Giradet, G. Gosselin, C. Perigaud, et al., Nucleosides Nucleotides, No. 14, 645–647 (1995).

  39. S. Benzaria, H. Pelicano, R. Johnson, et al., J. Med. Chem., No. 39, 4958–4965 (1996).

  40. I. Lefebvre, C. Perigaud, A. Pompon, et al., J. Med. Chem., No. 38, 3941–3950 (1995).

  41. G. Valette, A. Pompon, J. L. Giradet, et al., J. Med. Chem., No. 39, 1981–1990 (1996).

  42. C. Meier, Angew. Chem., No. 108, 77–79 (1996).

  43. M. Lorey, C. Meier, E. De Clerq, et al., Nucleosides Nucleotides, No. 16, 789–792 (1997).

  44. A. Bloch, M. J. Robins, and J. R. McCarthy, J. Med. Chem., No. 10, 908–912 (1967).

  45. C. Meier, T. Knispel, V. E. Marquez, et al., J. Med. Chem., No. 42, 1615–1624 (1999).

  46. C. McGuigan, M. J. Camarasa, H. Egberink, et al., Int. Antiviral News, No. 5, 19–21 (1997).

  47. S. S. Dhaneshwar and S. C. Chadurvedi, East. Pharm., No. 12, 119–122 (1996).

  48. N. Gairola, S. S. Dhaneshwar, and S. C. Chadurvedi, Indian J. Pharm. Sci., No. 67, 369–372 (2005).

  49. J. C. Burjaud and P. Delsoldato, Curr. Pharma. Des., No. 8, 206 (2002).

  50. V. R. Shanbhag and M. J. Crider, J. Pharm. Sci., No. 81, 149 (2002).

  51. T. V. Cai, X. Tang, and P. G. Vang, Bio. Org. Med. Chem., No. 11, 4971 (2003).

  52. A. A. Khan and J. K. Aroseq, Br. J. Clin. Pharmacol., No. 13, 523 (1982).

  53. C. P. Willoughby and E. Anderson, Gut, No. 23, 1081 (1982).

  54. C. E. Schacht, Macromol. Chem., No. 191, 529 (1990).

  55. J. S. Lee, Y. M. Kim, and Y. I. Jung, Drug. Dev. Ind. Pharm., No. 27, 331 (2001).

  56. Y. N. Pang, Z. R. Zhang and Y. Zhang, J. Gastroenterol., No. 15, 913 (2002).

  57. E. Roseeuw, G. Marchal, and D. Domurado, Antimicrob. Agents Chemother., No. 47, 34–35 (2003).

  58. A. Di Stefano, P. Sozio, and L. S. Cerasa, Molecules, No. 13, 46–68 (2008).

  59. N. Bodor and H. H. Farag, J. Med. Chem., No. 26, 528–534 (1983).

  60. I. K. Amin, H. Korideck, K. Wang, et al., Molecules, No. 13, 391–404 (2008).

  61. F. Leonelli F, A. La Bella, L. M. Migneco, et al., Molecules, No. 13, 360–378 (2008).

  62. G. L. Amidon, G. D. Leesman, and R. L. Elliott, J. Pharm. Sci., No. 69, 1363–1368 (1980).

  63. P. W. Swaan and J. J. Tukker, J. Pharmacol. Exp. Ther., No. 272, 242–247 (1995).

  64. H. K. Han and G. L. Amidon, AAPS Pharms., No. 6, 1–11, (2000).

  65. B. Pavan, A. Dalpiaz, N. Ciliberti, et al., Molecules, No. 13, 1035–1065 (2008).

  66. L. Perioli, V. Ambrogi, C. Bernardini, et al., Eur. J. Med. Chem., No. 39, 715–727 (2004).

  67. R. Kumar, L. Wang, L. I. Wiebe, et al., Arch. Pharm. Pharm. Med. Chem., No. 34, 351–356 (2001).

  68. H. S. Oz and L. Jeffrey, Molecules, No. 13, 452–474 (2008).

  69. S. B. Hanauer, Aliment. Pharmacol. Ther., Suppl No. 3, 37–40 (2006).

  70. S. S. Dhaneshwar, N. Gairola, M. Kandpal, et al., Bioorg. Med. Chem., No. 15, 4903–4909 (2007).

  71. M. G. Sandros, C. B. Sarraf, and M. Tabrizian, Molecules, No. 13, 1156–1178 (2008).

  72. S. S. Naik, J. F. Liang, Y. J. Park, et al., J. Control. Release. No. 101, 35–45 (2005).

  73. M. A. Abeer and P. A. Crooks, Molecules, No. 12, 373–388 (2007).

  74. M. R. Hellberg, T. L. Ke, K. Haggard, et al., J. Ocular Pharm. Ther., No. 19, 97–103 (2003).

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry, Sreevidhyaniketan College of Pharmacy, Tirupati, Andhra Pradesh, India

    A. Rasheed & C. K. A. Kumar

Authors
  1. A. Rasheed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. K. A. Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Rasheed.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s11094-009-0240-0

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rasheed, A., Kumar, C.K.A. Novel approaches on prodrug based drug design. Pharm Chem J 42, 677–686 (2008). https://doi.org/10.1007/s11094-009-0213-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-009-0213-3

Keywords

Search

Navigation